Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.40 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK4 | Q9NR20 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 3/20 | 0.39 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19836554 | 0.86 | CSNK1E (0.43) | SMN1; SMN2LMNATSHRHSD17B10CSNK1E | |
| SCHEMBL15345130 | 0.84 | HSD17B10 (0.42) | LMNATSHRHSD17B10CSNK1ECLK1 | |
| SCHEMBL9886621 | 0.82 | KDM4E (0.51) | SMN1; SMN2LMNAHSD17B10HDAC6HDAC3 | |
| SCHEMBL12205826 | 0.82 | TSHR (0.47) | SMN1; SMN2LMNATSHRHSD17B10CASR | |
| Hydrochloric Acid SCHEMBL11530947 | 0.81 | KDM4E (0.50) | SMN1; SMN2LMNAHSD17B10HDAC6HDAC3 | |
| SCHEMBL8130706 | 0.81 | CYP11B1 (0.45) | SMN1; SMN2CSNK1ECLK1CLK2CLK3 | |
| SCHEMBL1914100 | 0.81 | KDM4E (0.55) | LMNAHSD17B10CSNK1ECLK1CLK2 | |
| SCHEMBL12730097 | 0.81 | CASR (0.41) | SMN1; SMN2LMNATSHRHSD17B10FABP4 | |
| Hydrochloric Acid SCHEMBL11530944 | 0.79 | MAPT (0.49) | SMN1; SMN2LMNAHSD17B10HDAC6HDAC3 | |
| SCHEMBL11534871 | 0.78 | KDM4E (0.60) | SMN1; SMN2LMNATSHRHDAC1HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2018-05-10 | — | — | US | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
| US-4142886-A | Substituted benzimidazole compounds and use as herbicides | UNITED STATES BORAX & CHEMICAL CORPORATION (US) | 1979-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180127388-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | SMN1; SMN2 1111/4885LMNA 3781/4885TSHR 4662/4885 |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | SMN1; SMN2 1111/4885LMNA 3781/4885TSHR 4662/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | SMN1; SMN2 1111/4885LMNA 3781/4885TSHR 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.